Vantage logo

Biopharma buyouts still pricey

A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags.

Vantage logo

Bristol bets big on Myokardia

The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.